{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:52:53Z","timestamp":1794646373253,"version":"4.9.1"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"am","delay-in-days":294,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.neuropharm.2024.110227","type":"journal-article","created":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T22:58:52Z","timestamp":1731884332000},"page":"110227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Effects of genetic knockdown of the serotonin transporter on established L-DOPA-induced dyskinesia and gene expression in hemiparkinsonian rats"],"prefix":"10.1016","volume":"266","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8072-6853","authenticated-orcid":false,"given":"Grace","family":"McManus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Galfano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6339-7741","authenticated-orcid":false,"given":"Carla","family":"Budrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Lipari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuei Y.","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5802-5487","authenticated-orcid":false,"given":"Fredric P.","family":"Manfredsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4623-1085","authenticated-orcid":false,"given":"Christopher","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neuropharm.2024.110227_bib1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa\u2010related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.neuropharm.2024.110227_bib2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/jnr.24363","article-title":"Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: caution in experimental models of Parkinson's disease","volume":"97","author":"Albert","year":"2019","journal-title":"J. Neurosci. Res."},{"issue":"10","key":"10.1016\/j.neuropharm.2024.110227_bib3","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.3390\/cells9102265","article-title":"The multimodal serotonergic agent vilazodone inhibits L-DOPA-induced gene regulation in striatal projection neurons and associated dyskinesia in an animal model of Parkinson's disease","volume":"9","author":"Altwal","year":"2020","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.neuropharm.2024.110227_bib4","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.3390\/cells9102265","article-title":"The multimodal serotonergic agent vilazodone inhibits L-DOPA-induced gene regulation in striatal projection neurons and associated dyskinesia in an animal model of Parkinson's disease","volume":"9","author":"Altwal","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110227_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neuroscience.2008.07.016","article-title":"Exogenous corticosterone reduces l-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1\u03b2","volume":"156","author":"Barnum","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2024.110227_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-1-4939-3271-9_14","article-title":"Intraparenchymal stereotaxic delivery of rAAV and special considerations in vector handling","volume":"1382","author":"Benskey","year":"2016","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110227_bib7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/hgtb.2015.117","article-title":"Continuous collection of adeno-associated virus from producer cell medium significantly increases total viral yield","volume":"27","author":"Benskey","year":"2016","journal-title":"Hum. Gene Ther. Methods"},{"issue":"6","key":"10.1016\/j.neuropharm.2024.110227_bib8","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1111\/j.1460-9568.2012.08202.x","article-title":"Serotonin transporter inhibition attenuates <scp>l<\/scp> \u2010DOPA\u2010induced dyskinesia without compromising <scp>l<\/scp> \u2010DOPA efficacy in hemi\u2010parkinsonian rats","volume":"36","author":"Bishop","year":"2012","journal-title":"Eur. J. Neurosci."},{"issue":"7","key":"10.1016\/j.neuropharm.2024.110227_bib9","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/jnr.21978","article-title":"Contribution of the striatum to the effects of 5\u2010HT1A receptor stimulation in L\u2010DOPA\u2010treated hemiparkinsonian rats","volume":"87","author":"Bishop","year":"2009","journal-title":"J. Neurosci. Res."},{"issue":"10291","key":"10.1016\/j.neuropharm.2024.110227_bib10","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson's disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2024.110227_bib11","author":"Boudreau"},{"issue":"6","key":"10.1016\/j.neuropharm.2024.110227_bib12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3390\/cells12060837","article-title":"Broad serotonergic actions of vortioxetine as a promising avenue for the treatment of L-DOPA-induced dyskinesia","volume":"12","author":"Budrow","year":"2023","journal-title":"Cells"},{"issue":"4596","key":"10.1016\/j.neuropharm.2024.110227_bib13","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/1801200a0","article-title":"3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists","volume":"180","author":"Carlsson","year":"1957","journal-title":"Nat."},{"issue":"3","key":"10.1016\/j.neuropharm.2024.110227_bib14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/brain\/awh374","article-title":"Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors","volume":"128","author":"Carlsson","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2024.110227_bib15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuroscience.2011.07.070","article-title":"Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia","volume":"198","author":"Carta","year":"2011","journal-title":"Neurosci."},{"issue":"7","key":"10.1016\/j.neuropharm.2024.110227_bib16","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.neuropharm.2024.110227_bib17","first-page":"2694","article-title":"L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110227_bib18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1471-4159.2006.04124.x","article-title":"Post\u2010 versus presynaptic plasticity in L\u2010DOPA\u2010induced dyskinesia","volume":"99","author":"Cenci","year":"2006","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110227_bib19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0306-4522(98)00217-6","article-title":"Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions","volume":"88","author":"Chang","year":"1999","journal-title":"Neuroscience"},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2024.110227_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199855001-00001","article-title":"The significance of continuous dopaminergic stimulation in the treatment of Parkinson??s disease","volume":"55","author":"Chase","year":"1998","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.neuropharm.2024.110227_bib21","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3233\/JPD-240080","article-title":"Serotonergic regulation of synaptic dopamine levels mitigates L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease","volume":"14","author":"Chen","year":"2024","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2024.110227_bib22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pbb.2016.01.004","article-title":"Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats","volume":"142","author":"Conti","year":"2016","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2024.110227_bib23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.neuropharm.2016.07.025","article-title":"Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats","volume":"110","author":"Conti","year":"2016","journal-title":"Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2024.110227_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2013.09.017","article-title":"Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats","volume":"77","author":"Conti","year":"2014","journal-title":"Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2024.110227_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2023.148381","article-title":"Striatal serotonin transporter gain-of-function in L-DOPA-treated, hemi-parkinsonian rats","volume":"1811","author":"Conti Mazza","year":"2023","journal-title":"Brain Res."},{"issue":"7","key":"10.1016\/j.neuropharm.2024.110227_bib26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","article-title":"Modification of parkinsonism \u2014 chronic treatment with L-dopa","volume":"280","author":"Cotzias","year":"1969","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.neuropharm.2024.110227_bib27","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/syn.20630","article-title":"The role of the dorsal raphe nucleus in the development, expression, and treatment of L \u2010dopa\u2010induced dyskinesia in hemiparkinsonian rats","volume":"63","author":"Eskow","year":"2009","journal-title":"Synapse"},{"issue":"3","key":"10.1016\/j.neuropharm.2024.110227_bib28","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1600-0404.1966.tb01188.x","article-title":"Treatment of Parkinson\u2019s syndrome with l-dopa a double blind study","volume":"42","author":"Fehling","year":"2009","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.neuropharm.2024.110227_bib29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.neuroscience.2015.04.027","article-title":"Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease","volume":"298","author":"Fidalgo","year":"2015","journal-title":"Neurosci."},{"issue":"7","key":"10.1016\/j.neuropharm.2024.110227_bib30","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1007\/s00429-015-1125-5","article-title":"Serotonin hyperinnervation of the striatum with high synaptic incidence in parkinsonian monkeys","volume":"221","author":"Gagnon","year":"2016","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.neuropharm.2024.110227_bib31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.brainres.2016.05.027","article-title":"Sustained alterations in neuroimmune gene expression after daily, but not intermittent, alcohol exposure","volume":"1646","author":"Gano","year":"2016","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2024.110227_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.783893","article-title":"Striatal D1 dopamine neuronal population dynamics in a rat model of levodopa-induced dyskinesia","volume":"14","author":"Gao","year":"2022","journal-title":"Front. Aging Neurosci."},{"issue":"8","key":"10.1016\/j.neuropharm.2024.110227_bib33","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/mt.2010.115","article-title":"In vivo RNAi-mediated \u03b1-synuclein silencing induces nigrostriatal degeneration","volume":"18","author":"Gorbatyuk","year":"2010","journal-title":"Mol. Ther."},{"issue":"7092","key":"10.1016\/j.neuropharm.2024.110227_bib34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature04791","article-title":"Fatality in mice due to oversaturation of cellular microRNA\/short hairpin RNA pathways","volume":"441","author":"Grimm","year":"2006","journal-title":"Nat."},{"key":"10.1016\/j.neuropharm.2024.110227_bib35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.physbeh.2013.10.035","article-title":"The inflamed axis: the interaction between stress, hormones, and the expression of inflammatory-related genes within key structures comprising the hypothalamic-pituitary-adrenal axis","volume":"124","author":"Hueston","year":"2014","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2024.110227_bib36","article-title":"Monoamine reuptake inhibitors in Parkinson's disease","volume":"2015","author":"Huot","year":"2015","journal-title":"Parkinson's Dis."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110227_bib37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1254\/jphs.12003FP","article-title":"Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on L-DOPA-induced rotational behavior in a hemiparkinsonian rat model","volume":"119","author":"Inden","year":"2012","journal-title":"J. Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.neuropharm.2024.110227_bib38","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1124\/jpet.106.110429","article-title":"In 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\\ increased motor disability","volume":"319","author":"Iravani","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"S11","key":"10.1016\/j.neuropharm.2024.110227_bib39","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/mds.20458","article-title":"Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations","volume":"20","author":"Jankovic","year":"2005","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.neuropharm.2024.110227_bib40","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson's disease: clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2024.110227_bib41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neulet.2006.03.059","article-title":"Reuptake of l-DOPA-derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters","volume":"402","author":"Kannari","year":"2006","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110227_bib42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1046\/j.1471-4159.2000.0740263.x","article-title":"Reserpine pretreatment prevents increases in extracellular striatal dopamine following L\u2010DOPA administration in rats with nigrostriatal denervation","volume":"74","author":"Kannari","year":"2000","journal-title":"J. Neurochem."},{"issue":"0","key":"10.1016\/j.neuropharm.2024.110227_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-002-1204-4","article-title":"Treatment of Parkinson's disease: levodopa as the first choice","volume":"249","author":"Katzenschlager","year":"2002","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110227_bib44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0092-8674(03)00801-8","article-title":"Functional siRNAs and miRNAs exhibit strand bias","volume":"115","author":"Khvorova","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2024.110227_bib45","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.neuroscience.2016.06.017","article-title":"L-DOPA-induced dyskinesia is associated with a deficient numerical downregulation of striatal tyrosine hydroxylase mRNA-expressing neurons","volume":"331","author":"Klietz","year":"2016","journal-title":"Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110227_bib46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.nbd.2004.07.005","article-title":"Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia","volume":"17","author":"Konradi","year":"2004","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110227_bib47","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00213-007-1030-6","article-title":"The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram","volume":"197","author":"Kuan","year":"2008","journal-title":"Psychopharmacol."},{"issue":"8","key":"10.1016\/j.neuropharm.2024.110227_bib48","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00702-017-1837-1","article-title":"Serotonergic targets for the treatment of l-DOPA-induced dyskinesia","volume":"125","author":"Lanza","year":"2018","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2024.110227_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113534","article-title":"Genetic suppression of the dopamine D3 receptor in striatal D1 cells reduces the development of L-DOPA-induced dyskinesia","volume":"336","author":"Lanza","year":"2021","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2024.110227_bib50","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neurobiolaging.2019.05.019","article-title":"Late aging\u2013associated increases in L-DOPA\u2013induced dyskinesia are accompanied by heightened neuroinflammation in the hemi-parkinsonian rat","volume":"81","author":"Lanza","year":"2019","journal-title":"Neurobiol. Aging"},{"issue":"17","key":"10.1016\/j.neuropharm.2024.110227_bib51","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1523\/JNEUROSCI.0576-11.2011","article-title":"Dopamine transport by the serotonin transporter: a mechanistically distinct mode of substrate translocation","volume":"31","author":"Larsen","year":"2011","journal-title":"J. Neurosci."},{"issue":"10","key":"10.1016\/j.neuropharm.2024.110227_bib52","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1212\/WNL.0000000000001909","article-title":"Putaminal serotonergic innervation","volume":"85","author":"Lee","year":"2015","journal-title":"Neurol"},{"issue":"230","key":"10.1016\/j.neuropharm.2024.110227_bib53","first-page":"535","article-title":"L-dopa treatment and Parkinson's disease","volume":"59","author":"Lees","year":"1986","journal-title":"Q. J. Med."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110227_bib54","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1353-8020(99)00050-4","article-title":"Worsening of Parkinson's disease by citalopram","volume":"6","author":"Linazasoro","year":"2000","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110227_bib55","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/bph.12894","article-title":"Side effect profile of 5\u2010HT treatments for Parkinson\u2019s disease and L\u2010DOPA\u2010induced dyskinesia in rats","volume":"172","author":"Lindenbach","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2024.110227_bib56","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/j.1471-4159.2009.06556.x","article-title":"L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia","volume":"112","author":"Lindgren","year":"2010","journal-title":"J. Neurochem."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2024.110227_bib57","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0006-8993(98)01248-7","article-title":"Loss of regulation by presynaptic dopamine D 2 receptors of exogenous l -DOPA-derived dopamine release in the dopaminergic denervated striatum","volume":"817","author":"Maeda","year":"1999","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110227_bib59","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.nbd.2012.03.001","article-title":"Regulated protein expression for in vivo gene therapy for neurological disorders: progress, strategies, and issues","volume":"48","author":"Manfredsson","year":"2012","journal-title":"Neurobiol. Dis."},{"issue":"46","key":"10.1016\/j.neuropharm.2024.110227_bib58","first-page":"204","article-title":"Development of gene therapy for neurological disorders","volume":"9","author":"Manfredsson","year":"2010","journal-title":"Discov. Med."},{"issue":"7","key":"10.1016\/j.neuropharm.2024.110227_bib60","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1007\/s00415-024-12400-6","article-title":"The chronic use of serotonin norepinephrine reuptake inhibitors facilitates dyskinesia priming in early Parkinson's disease","volume":"271","author":"Marano","year":"2024","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.neuropharm.2024.110227_bib61","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/ane.12314","article-title":"Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease","volume":"131","author":"Mazzucchi","year":"2015","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.neuropharm.2024.110227_bib62","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.expneurol.2017.03.013","article-title":"Characterizing the differential roles of striatal 5-HT 1A auto- and hetero-receptors in the reduction of l -DOPA-induced dyskinesia","volume":"292","author":"Meadows","year":"2017","journal-title":"Exp. Neurol."},{"issue":"11","key":"10.1016\/j.neuropharm.2024.110227_bib63","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/mds.100","article-title":"Diverse serotonin actions of vilazodone reduce l\u20103,4\u2010dihidroxyphenylalanine\u2013induced dyskinesia in hemi\u2010parkinsonian rats","volume":"33","author":"Meadows","year":"2018","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110227_bib64","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1212\/WNL.48.2.369","article-title":"Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications","volume":"48","author":"Metman","year":"1997","journal-title":"Neurol"},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110227_bib65","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0006-8993(93)91449-3","article-title":"l-Dopa stimulates c-fos expression in dopamine denervated striatum by combined activation of D-1 and D-2 receptors","volume":"623","author":"Morelli","year":"1993","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110227_bib66","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1006\/exnr.2002.7976","article-title":"Behavioral and anatomical effects of long-term ?-Dihydroxyphenylalanine (L-DOPA) administration in rats with unilateral lesions of the nigrostriatal system","volume":"177","author":"Mura","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2024.110227_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fnana.2011.00051","article-title":"Striatal signaling in L-DOPA-induced dyskinesia: common mechanisms with drug abuse and long term memory involving D1 dopamine receptor stimulation","volume":"5","author":"Murer","year":"2011","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.neuropharm.2024.110227_bib68","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1471-1931(00)00031-8","article-title":"Levodopa motor complications in Parkinson's disease","volume":"23","author":"Obeso","year":"2000","journal-title":"Trends Neurosci."},{"issue":"9","key":"10.1016\/j.neuropharm.2024.110227_bib69","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1111\/j.1460-9568.2012.08243.x","article-title":"Anti\u2010dyskinetic mechanisms of amantadine and dextromethorphan in the 6\u2010OHDA rat model of Parkinson's disease: role of NMDA vs. 5\u2010HT1A receptors","volume":"36","author":"Paquette","year":"2012","journal-title":"Eur. J. Neurosci."},{"issue":"9","key":"10.1016\/j.neuropharm.2024.110227_bib70","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nmeth911","article-title":"On the art of identifying effective and specific siRNAs","volume":"3","author":"Pei","year":"2006","journal-title":"Nat. Methods"},{"key":"10.1016\/j.neuropharm.2024.110227_bib71","author":"Phillips Iii"},{"key":"10.1016\/j.neuropharm.2024.110227_bib72","author":"Prashanth"},{"key":"10.1016\/j.neuropharm.2024.110227_bib73","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.expneurol.2013.06.015","article-title":"Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease","volume":"248","author":"Prinz","year":"2013","journal-title":"Exp. Neurol."},{"issue":"8","key":"10.1016\/j.neuropharm.2024.110227_bib74","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/sj.mt.6300227","article-title":"Time course of transgene expression after intrastriatal pseudotyped rAAV2\/1, rAAV2\/2, rAAV2\/5, and rAAV2\/8 transduction in the rat","volume":"15","author":"Reimsnider","year":"2007","journal-title":"Mol. Ther. : J. Am. Soc. Gene Ther."},{"issue":"12","key":"10.1016\/j.neuropharm.2024.110227_bib75","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1212\/WNL.0000000000002494","article-title":"Serotonin-to-dopamine transporter ratios in Parkinson disease","volume":"86","author":"Roussakis","year":"2016","journal-title":"Neurol."},{"issue":"5","key":"10.1016\/j.neuropharm.2024.110227_bib76","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa\u2010induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2024.110227_bib77","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-1-4939-9065-8_6","article-title":"Multimodal production of adeno-associated virus","volume":"1937","author":"Sandoval","year":"2019","journal-title":"Methods Mol. Biol."},{"issue":"12","key":"10.1016\/j.neuropharm.2024.110227_bib78","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1248\/bpb.17.1616","article-title":"Pharmacokinetic and pharmacodynamic studies of L-dopa in rats. I. Pharmacokinetic analysis of L-dopa in rat plasma and striatum","volume":"17","author":"Sato","year":"1994","journal-title":"Biol. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110227_bib79","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40478-018-0653-7","article-title":"Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia","volume":"7","author":"Sellnow","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"issue":"18","key":"10.1016\/j.neuropharm.2024.110227_bib80","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1523\/JNEUROSCI.2936-19.2020","article-title":"Striatal Nurr1 facilitates the dyskinetic state and exacerbates levodopa-induced dyskinesia in a rat model of Parkinson's disease","volume":"40","author":"Sellnow","year":"2020","journal-title":"J. Neurosci. : Off. J. Soc. Neurosci."},{"issue":"7","key":"10.1016\/j.neuropharm.2024.110227_bib81","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s00213-022-06078-9","article-title":"The effects of Vilazodone, YL-0919 and Vortioxetine in hemiparkinsonian rats","volume":"239","author":"Smith","year":"2022","journal-title":"Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110227_bib82","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00002826-199704000-00001","article-title":"Strategies for treating patients with advanced Parkinson\u02bcs disease with disastrous fluctuations and dyskinesias","volume":"20","author":"Stocchi","year":"1997","journal-title":"Clin. Neuropharmacol."},{"issue":"6_Suppl. l_6","key":"10.1016\/j.neuropharm.2024.110227_bib83","article-title":"History of levodopa and dopamine agonists in Parkinson's disease treatment","volume":"50","author":"Tolosa","year":"1998","journal-title":"Neurol"},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110227_bib84","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.neures.2005.03.004","article-title":"A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to l-DOPA in a rodent model of Parkinson's disease","volume":"52","author":"Tomiyama","year":"2005","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2024.110227_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2020.147266","article-title":"Inhibition of striatal dopamine D5 receptor attenuates levodopa-induced dyskinesia in a rat model of Parkinson's disease","volume":"1754","author":"Wang","year":"2021","journal-title":"Brain Res."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824003964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824003964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T12:12:49Z","timestamp":1737288769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390824003964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":85,"alternative-id":["S0028390824003964"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110227","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of genetic knockdown of the serotonin transporter on established L-DOPA-induced dyskinesia and gene expression in hemiparkinsonian rats","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110227"}}